EX-23.1 4 atxs-20241231xex23d1.htm EX-23.1

Exhibit 23.1

​

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

| 1) | Registration Statement (Form S-8 No.333-281491, 333-263459, 333-273773) pertaining to the Second Amended and Restated 2015 Stock Incentive Plan, the 2015 Employee Stock Purchase Plan and the 2022 Inducement Stock Incentive Plan, as amended of Astria Therapeutics, Inc.,

| 2) | Registration Statement (Form S-8 No. 333-206394) pertaining to the Amended and Restated 2008 Equity Incentive Plan, as amended, the 2015 Stock Incentive Plan and 2015 Employee Stock Purchase Plan of Astria Therapeutics, Inc.,

| 3) | Registration Statement (Form S-8 Nos. 333-210229, 333-216793, 333-223721) pertaining to the 2015 Stock Incentive Plan and 2015 Employee Stock Purchase Plan of Astria Therapeutics, Inc.,

| 4) | Registration Statement (Form S-8 Nos. 333-229643, 333-239114, 333-258633) pertaining to the Amended and Restated 2015 Stock Incentive Plan and 2015 Employee Stock Purchase Plan of Astria Therapeutics, Inc.,

| 5) | Registration Statement (Form S-3 Nos. 333-254174, 333-264911, 333-271848, and 333-276057) of Astria Therapeutics, Inc.;

of our report dated March 11, 2025, with respect to the consolidated financial statements of Astria Therapeutics, Inc. included in this Annual Report (Form 10-K) of Astria Therapeutics, Inc. for the year ended December 31, 2024.

​

/s/ Ernst & Young LLP

​

Boston, Massachusetts

March 11, 2025